U.S. markets closed

Novacyt S.A. (NVYTF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
4.1800+0.4800 (+12.97%)
At close: 1:03PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close3.7000
BidN/A x N/A
AskN/A x N/A
Day's Range4.1800 - 4.1800
52 Week Range0.6595 - 6.5500
Avg. Volume2,527
Market CapN/A
Beta (5Y Monthly)-2.24
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Business Wire

    Novacyt S.A. ("Novacyt" or the "Company"): US FDA Emergency Use Authorization for COVID-19 Diagnostic Test

    Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, is pleased to announce that the US Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for its COVID-19 test. As a result, hospitals and laboratories in the US will be able to use the test for clinical diagnosis of COVID-19. The test is available for immediate distribution into the US market.